Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Smith & Nephew plc (SNN) Price & Performance

Heron Therapeutics IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Smith & Nephew plc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: Smith & Nephew plc is far larger — about 197.1× Heron Therapeutics Inc's market cap, and Smith & Nephew plc pays a 2.64% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXSNN
Market Cap
$63.41M$12.50B
Sector
HealthHealth
52-Week High
$1.49$38.70
52-Week Low
$0.32$28.73
Enterprise Value
$161.31M$15.53B
Dividend Yield
2.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Smith & Nephew plc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN